# AI Doctor Tool Doubles Value in $250M Funding Boost
OpenEvidence, the leading AI platform revolutionizing medical decision-making for healthcare professionals, has secured a massive $250 million Series D funding round, doubling its valuation to $12 billion.[1][4] This landmark investment, announced on Wednesday, underscores surging investor confidence in AI-driven healthcare tools amid explosive growth in clinical adoption and revenue.[1][4]
OpenEvidence's Rapid Rise: From Startup to $12B Powerhouse
OpenEvidence, a Miami-based AI innovator founded in 2021, has transformed into a "brain extender" for doctors by delivering citation-linked answers from medical literature via a specialized medical search engine.[4][6] The platform, which is free for physicians and ad-supported, hit $100 million in annual revenue by January and now supports 18 million clinical consultations monthly from verified U.S. physicians—up from 3 million a year ago.[4] Surveys rank it as the top AI tool among doctors, with 45% usage surpassing nine competitors, and it's deployed daily by over 40% of U.S. physicians across 10,000+ hospitals.[4][5]
This Series D round, co-led by Thrive Capital and DST, marks OpenEvidence's fourth fundraise in under a year, bringing total funding to nearly $700 million since inception.[4] Backers include heavyweights like GV, Sequoia Capital, Kleiner Perkins, and Coatue, signaling strong belief in its potential to outpace generalist AI health offerings from players like OpenAI and Anthropic.[4]
Funding Fuels AI Expansion in Booming Health Tech Sector
The $250 million infusion arrives as AI healthcare funding surges globally, with $14 billion invested in seed-to-growth stage companies in 2025 alone—a 63% jump from 2024's $8.6 billion.[4] OpenEvidence plans to accelerate development of its core platform, enhancing real-time support for life-saving decisions and patient care, as stated by CEO Daniel Nadler.[6] With proven daily reliance by clinicians, the tool addresses high-pain areas like diagnostics and treatment by safely augmenting physician expertise with evidence-based insights.[4][6]
Unlike fragmented tools, OpenEvidence's model emphasizes safety and verifiability, positioning it as indispensable amid rising administrative burdens and competitive pressures in healthcare.[1][4]
What Sets OpenEvidence Apart from Competitors
OpenEvidence differentiates itself through hyper-specialization: it provides precise, literature-backed responses tailored for clinical use, achieving unmatched adoption rates.[1][5] While big AI firms roll out broad "health" features, OpenEvidence's focus on verified physicians and hospital integration has driven 6x consultation growth year-over-year.[4] Its ad-supported, free-to-doctors approach democratizes access, fueling rapid scaling and revenue without user fees.[4]
Investor enthusiasm reflects this edge, with the valuation doubling from $6 billion post-Series C in October, highlighting AI's role in tackling healthcare's high-cost inefficiencies.[1][4]
Investor Confidence Signals Broader AI Healthcare Revolution
This deal exemplifies a mandate for AI to "eliminate the squeeze" on providers, mirroring trends in platforms like Tebra but centered on clinical intelligence.[2] As AI health tech funding hits record highs, OpenEvidence's trajectory points to a future where tools like these restore focus on patient care over paperwork.[3][4]
Frequently Asked Questions
What is OpenEvidence?
OpenEvidence is an AI-powered medical search engine and "brain extender" for doctors, offering citation-linked answers from medical literature to support clinical decisions. It's free for physicians, ad-supported, and used daily by over 40% of U.S. doctors.[4][6]
How much funding did OpenEvidence raise and at what valuation?
The company closed a $250 million Series D round, doubling its valuation to $12 billion from $6 billion in its prior round.[1][4]
Who led OpenEvidence's latest funding round?
Thrive Capital and DST co-led the Series D, with participation from GV, Sequoia Capital, Kleiner Perkins, Coatue, and others.[4]
What is OpenEvidence's revenue and user growth?
It reached $100 million in annual revenue by January and now handles 18 million monthly clinical consultations, up from 3 million a year ago.[4]
Why is OpenEvidence the top AI tool for doctors?
A survey shows 45% of physicians use it, more than any other AI tool, due to its specialized, evidence-based support in hospitals and clinics.[4][5]
How does this funding impact AI in healthcare?
The investment accelerates platform development amid $14 billion in 2025 AI health tech funding, a 63% rise from 2024, signaling a shift toward scalable clinical AI.[4]
🔄 Updated: 1/21/2026, 6:20:11 PM
**OpenEvidence doubles valuation to $12 billion** in a $250 million Series D funding round led by Thrive Capital and DST, marking the AI medical search platform's fourth fundraise in less than a year[4]. The Miami-based startup, which reached $100 million in annual revenue this month, supported approximately 18 million clinical consultations from verified U.S. physicians in December—a dramatic increase from 3 million monthly consultations a year ago—and is now used daily by more than 40% of American physicians across over 10,000 hospitals[4]. The funding from investors including Sequoia Capital, Kleiner Perkins, and Coatue
🔄 Updated: 1/21/2026, 6:30:12 PM
**OpenEvidence Doubles Valuation to $12B in $250M Series D**
OpenEvidence, an AI-powered medical search engine for clinicians, announced Wednesday it has raised $250 million in Series D funding that doubled its valuation from $6 billion to $12 billion in just three months, with the round co-led by Thrive Capital and DST Global[3][4]. The platform, which has raised $700 million total since 2021, now supports approximately 18 million clinical consultations monthly from verified U.S. physicians and is used daily by more than 40% of physicians across over 10,000 hospitals and medical centers[3]. The
🔄 Updated: 1/21/2026, 6:40:10 PM
**NEWS UPDATE: OpenEvidence AI Doctor Tool Doubles Valuation to $12B in $250M Series D Boost**
OpenEvidence, the leading AI "brain extender" for clinicians used by **45% of U.S. physicians** daily across **10,000+ hospitals**, doubled its valuation to **$12 billion** in a $250M Series D co-led by Thrive Capital and DST Global, signaling VC confidence in specialized medical AI over generalist rivals like OpenAI and Anthropic[3][4][7]. Experts note VCs are betting on doctor-focused workflows amid **$14B in 2025 AI health tech funding** (up 63% from 2024), with backers like Sequoia, Kl
🔄 Updated: 1/21/2026, 6:50:21 PM
**OpenEvidence, an AI-powered "brain extender" for doctors, secured $250 million in Series D funding, doubling its valuation to $12 billion just three months after its $6 billion Series C.** The platform functions as a specialized medical search engine, delivering citation-linked answers from literature to support clinical decisions, powering 18 million U.S. physician consultations in December—up from 3 million monthly a year prior—and claiming daily use by over 40% of U.S. doctors across 10,000+ hospitals.[4][5][7] This funding, co-led by Thrive Capital and DST amid rising AI health tech investment ($14B in 2025), underscores investor confidence in workflow-specific tools over generalist rivals lik
🔄 Updated: 1/21/2026, 7:00:21 PM
**NEWS UPDATE: OpenEvidence's $250M Funding Signals Global AI Healthcare Boom**
OpenEvidence's $250 million Series D round, doubling its valuation to **$12 billion**, underscores surging global investor confidence in AI-powered health tech, with **$14 billion** poured into the sector in 2025 alone—up 63% from **$8.6 billion** in 2024.[2] The Miami-based platform, now supporting **18 million monthly U.S. clinical consultations** across **10,000+ hospitals** and used daily by over **40% of U.S. physicians**, is poised for international expansion amid VCs betting specialized doctor tools outpace general AI like OpenAI's ChatGPT Health.[2][
🔄 Updated: 1/21/2026, 7:10:19 PM
**OpenEvidence's AI platform for doctors doubled its valuation to $12 billion in a $250 million Series D round co-led by Thrive Capital and DST Global, announced Wednesday, bringing total funding to nearly $700 million since 2021.**[3][4][5] The tool functions as a specialized medical search engine delivering citation-linked answers from literature as a clinician "brain extender," powering 18 million U.S. clinical consultations in December—up from 3 million monthly a year ago—and daily use by over 40% of U.S. physicians across 10,000+ hospitals, with $100 million annual revenue from its free, ad-supported model.[3][4][6] This funding signals investor confidence in specialize
🔄 Updated: 1/21/2026, 7:20:18 PM
**OpenEvidence doubles valuation to $12 billion in $250M Series D**, signaling venture capitalist confidence that specialized medical AI platforms will thrive despite competition from consumer-focused health tools launched by OpenAI and Anthropic.[3][4] The company, which serves 40% of U.S. physicians across 10,000+ hospitals and reached $100 million in annual revenue, occupies a distinctly different competitive lane—functioning as a clinical workflow tool for doctors during patient consultations rather than a consumer health product.[3][4] Investors backing the round, including Thrive Capital, DST Global, and Mayo Clinic, are essentially betting that specialized medical platforms will "carve
🔄 Updated: 1/21/2026, 7:30:21 PM
I cannot provide a news update on regulatory or government response to OpenEvidence's $250M funding round, as the search results contain no information about regulatory actions, government statements, or policy responses to this funding announcement.[1][2][3][4][5][6][7][8] The available sources focus exclusively on the funding details, valuation increase to $12 billion, investor participation, and the platform's clinical adoption metrics. To answer your query accurately, I would need search results that specifically address government or regulatory commentary on this development.
🔄 Updated: 1/21/2026, 7:40:21 PM
**OpenEvidence, the AI platform dominating clinical workflows, doubled its valuation to $12 billion in a $250 million Series D round co-led by Thrive Capital and DST Global, signaling investor confidence that specialized medical tools will thrive despite OpenAI and Anthropic's newly launched consumer health products.[2][3]** The funding sprint reflects a strategic bet that OpenEvidence's deep integration into doctor-patient consultations—supporting 18 million clinical consultations in December alone—operates in a fundamentally different lane than broad consumer health AI, with the platform now used daily by over 40% of U.S. physicians across 10,000+ hospitals.[2] The roun
🔄 Updated: 1/21/2026, 7:50:20 PM
**OpenEvidence doubles valuation to $12 billion in $250M Series D round**
Medical AI platform OpenEvidence announced Wednesday it has raised $250 million in Series D funding, doubling its valuation from $6 billion in October to $12 billion[3][4]. The round was co-led by Thrive Capital and DST Global and included backing from Sequoia Capital, Kleiner Perkins, Coatue, and Mayo Clinic, signaling strong investor confidence in the specialized medical AI sector despite recent launches of health tools from OpenAI and Anthropic[3][4].
However, the search results provided do not contain information about market reactions or stock
🔄 Updated: 1/21/2026, 8:00:22 PM
**OpenEvidence's $250M Series D, doubling its valuation to $12B, intensifies competition in AI doctor tools by outpacing generalist entrants like OpenAI's ChatGPT Health and Anthropic's Claude for Healthcare.** Investors, including Thrive Capital, DST, Sequoia, and Kleiner Perkins, signaled confidence in specialized clinical platforms, with VCs betting "specialized medical platforms will carve out their own turf" amid $14B in 2025 AI health tech funding—up 63% from 2024[4][5]. OpenEvidence now claims 45% physician usage as the top AI tool, supporting 18M monthly U.S. consultations versus rivals' broader consumer/payer focus
🔄 Updated: 1/21/2026, 8:10:18 PM
**OpenEvidence Doubles Valuation to $12 Billion in $250M Series D**
Medical AI platform OpenEvidence announced a $250 million Series D funding round on Wednesday that doubled its valuation to $12 billion in just three months, with co-leads Thrive Capital and DST Global backing the Miami-based startup alongside heavyweight investors including Sequoia Capital, Kleiner Perkins, and Mayo Clinic.[4][5] The platform, which serves as a specialized medical search engine for clinicians, now supports approximately 18 million monthly clinical consultations from verified U.S. physicians and is used daily by over 40% of American doctors across more than 10,
🔄 Updated: 1/21/2026, 8:20:19 PM
**OpenEvidence, an AI medical search platform for physicians, doubled its valuation to $12 billion in a Series D funding round led by Thrive Capital and DST Global, raising $250 million**[3][4]. The Miami-based startup has now raised nearly $700 million since its 2021 inception, with the company supporting 18 million clinical consultations in December—up from 3 million monthly consultations a year ago—and is used daily by over 40% of U.S. physicians across more than 10,000 hospitals[3]. The funding comes as OpenEvidence reached $100 million in annual revenue in January and faces competition from consumer health AI tools
🔄 Updated: 1/21/2026, 8:30:20 PM
OpenEvidence, a **clinical AI platform**, announced a $250 million Series D funding round on Wednesday that **doubled its valuation to $12 billion** in just three months, signaling investor confidence that specialized medical AI tools can compete alongside broader health offerings from OpenAI and Anthropic[2][3]. The funding reflects strong market traction, with OpenEvidence supporting approximately 18 million clinical consultations in December and serving over 40% of U.S. physicians across 10,000+ hospitals[2]. Venture capitalists' continued backing demonstrates their belief that doctor-focused platforms operating within clinical workflows will "carve out their own turf" distinct from consumer-facing health AI, with
🔄 Updated: 1/21/2026, 8:40:21 PM
**OpenEvidence, a clinical AI platform, doubled its valuation to $12 billion in a $250 million Series D funding round co-led by Thrive Capital and DST Global, achieving this valuation increase in just three months after its October Series C at $6 billion.[4][5]** The platform, which serves as a medical search engine providing citation-linked clinical guidance to physicians, supported approximately 18 million clinical consultations in December and is used daily by over 40% of U.S. physicians across 10,000+ hospitals.[4] **The funding demonstrates investor confidence that specialized medical AI platforms will maintain distinct market positioning against broader health offerings from OpenAI and Anthropic